Femme et Homme
- | Pays :
- Japan
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the dose-response efficacy of E2020 (5 mg/day and 10 mg/day) versus placebo and verify superiority of E2020 to placebo in patients with severe AD using CIBIC-plus* and SIB** as the primary efficacy measures. Safety of E2020 will also be evaluated. (*for overall evalution of clinical symtoms) (**for cognitive function test)
Critère d'inclusion
- Alzheimer Disease